.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Immunotherapy targeting the PD-1/PD-L1 pathway has transformed breast cancer treatment. However, clinicians often struggle to predict which patients will benefit most. While immunohistochemistry (IHC) is the standard tool, it frequently misses glycosylated PD-L1 (gPD-L1) due to glycan-mediated epitope shielding. To bridge this gap, researchers recently introduced the CAP-g bioplatform for ultrasensitive gPD-L1-sEV detection. This breakthrough offers a more accurate way to assess immune-checkpoint blockade (ICB) response.
The CAP-g platform utilizes a specialized 3D CF/DPEDOT:PSS/Au nanoflexible scaffold. This design significantly improves electron transfer efficiency by minimizing charge-transfer resistance. Furthermore, the system employs a dual-recognition-driven proximity cascade amplification. Specifically, the co-anchoring of a PD-L1 aptamer and a glycan probe triggers a hybridization chain reaction (HCR). Consequently, this method achieves a limit of detection 100 times lower than conventional immunological strategies.
Early clinical validation indicates that this technology reliably distinguishes breast cancer patients from healthy individuals. Because gPD-L1 regulates tumor progression and immune suppression, accurate gPD-L1-sEV detection provides vital prognostic data. Most importantly, the platform operates effectively across a broad linear dynamic range. Therefore, it addresses the \"detection blind spot\" that currently hinders precision oncology in India and globally.
Standard immunohistochemistry often fails because glycans physically shield the PD-L1 epitope. This shielding prevents diagnostic antibodies from binding, leading to false-negative results and poor immunotherapy predictions.
The platform uses a 3D nanonetwork scaffold combined with a dual-aptamer proximity cascade. This setup minimizes electrical resistance and triggers a hybridization chain reaction, allowing for 100 times greater sensitivity than existing tests.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Qiu X et al. Flexible Dual-Apt Scaffolds Reveal gPD-L1-sEVs in Breast Cancer. Anal Chem. 2026 May 01. doi: 10.1021/acs.analchem.6c01173. PMID: 42065221.
Li H et al. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. J Hematol Oncol. 2020;13(1):1. doi: 10.1186/s13045-019-0841-8.
Yang Q et al. Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer. Front Oncol. 2024. doi: 10.3389/fonc.2024.1354210.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new ultrasensitive CAP-g platform detects glycosylated PD-L1 in breast cancer, overcoming IHC limitations to improve immunotherapy response prediction....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
